Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Payables (2021 - 2025)

Lyra Therapeutics has reported Payables over the past 5 years, most recently at $663000.0 for Q4 2025.

  • Quarterly results put Payables at $663000.0 for Q4 2025, down 43.77% from a year ago — trailing twelve months through Dec 2025 was $663000.0 (down 43.77% YoY), and the annual figure for FY2025 was $663000.0, down 43.77%.
  • Payables for Q4 2025 was $663000.0 at Lyra Therapeutics, up from $627000.0 in the prior quarter.
  • Over the last five years, Payables for LYRA hit a ceiling of $5.1 million in Q3 2023 and a floor of $627000.0 in Q3 2025.
  • Median Payables over the past 5 years was $2.5 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Payables: soared 150.78% in 2023 and later crashed 86.32% in 2025.
  • Lyra Therapeutics' Payables stood at $3.1 million in 2021, then dropped by 16.29% to $2.6 million in 2022, then rose by 19.69% to $3.1 million in 2023, then plummeted by 62.34% to $1.2 million in 2024, then plummeted by 43.77% to $663000.0 in 2025.
  • The last three reported values for Payables were $663000.0 (Q4 2025), $627000.0 (Q3 2025), and $680000.0 (Q2 2025) per Business Quant data.